Trial Outcomes & Findings for Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening (NCT NCT04498052)

NCT ID: NCT04498052

Last Updated: 2025-03-24

Results Overview

The LCS care gap was considered closed if one or more of the following events occurred: (1) LDCT completion in the past year, (2) completion of another chest CT in the past year, or (3) SDM documentation in the past 3 years for eligible patients. To assess population care-gap closure levels at the end of each study period, we estimated the care-gap closure status for all patients who had primary care visits in the 12 months preceding the last day of the period. Using structured EHR data, SDM was considered documented if a clinician noted the need for LCS discussion was addressed, the patient declined screening, or LCS was not appropriate.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

1855 participants

Primary outcome timeframe

Through study completion, an average of 18 months for the intervention period and 12 months for the baseline period

Results posted on

2025-03-24

Participant Flow

This is a non-randomized control study, where all eligible patients who had a visit in a pre-specified time period were assigned to that period. Therefore, some patients in periods 1 and 2 were the same, but some were different, resulting in 1855 patients in total, including 1104 in the baseline period, 1219 patients in period 1, and 1255 patients in period 2.

Participant milestones

Participant milestones
Measure
Patients Eligible for LDCT Lung Cancer Screening
This population will consist of patients eligible for, or potentially eligible for, LDCT lung cancer screening according to 2013 USPSTF guidelines. The inclusion criteria are (i) \>= 55 years and \<= 80 years old at the time of the visit; (ii) does not already have lung cancer; and (iii) meets USPSTF smoking criteria for LDCT screening (30+ pack-year smoking history and current smoker or quit in the past 15 years) or may meet the criteria if a complete smoking history were taken.
Period 1 (Clinician-facing Intervention)
STARTED
1219
Period 1 (Clinician-facing Intervention)
COMPLETED
1219
Period 1 (Clinician-facing Intervention)
NOT COMPLETED
0
Period 2 (Clinician + Patient Tools)
STARTED
1255
Period 2 (Clinician + Patient Tools)
COMPLETED
1255
Period 2 (Clinician + Patient Tools)
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Participants
n=1104 Participants
Study eligibility criteria were evaluated at the level of primary care visits (office visits or telehealth visits) during the study period. Patients were eligible if they met 2013 USPSTF LCS eligibility criteria at the time of the visit and had at least 1 primary care visit in the preceding year. Per USPSTF guidelines, a person qualified for LCS if they were aged 55 to 80 years, had a smoking history of 30 pack-years or greater, actively smoked or had quit in the previous 15 years, and had not been diagnosed with lung cancer.
Age, Continuous
65.0 years
n=99 Participants
Sex: Female, Male
Female
470 Participants
n=99 Participants
Sex: Female, Male
Male
634 Participants
n=99 Participants
Race/Ethnicity, Customized
Black or African American, non-Hispanic
20 Participants
n=99 Participants
Race/Ethnicity, Customized
Hispanic, any race
59 Participants
n=99 Participants
Race/Ethnicity, Customized
White, non-Hispanic
946 Participants
n=99 Participants
Race/Ethnicity, Customized
Other
79 Participants
n=99 Participants
Region of Enrollment
United States
1104 participants
n=99 Participants
No. visits per patient
3.0 visits
n=99 Participants
High-benefit personalized screening benefit level
694 Participants
n=99 Participants
>= 1 pulmonary visit in study period
42 Participants
n=99 Participants
Time smoked
40.0 years
n=99 Participants
Cigarettes per day
20.0 cigarettes per day
n=99 Participants
Current smoker
550 Participants
n=99 Participants
Former smoker (quit < 15 y ago)
554 Participants
n=99 Participants
Time since last smoked
7.0 years
n=99 Participants
Insurance
Commercial
337 Participants
n=99 Participants
Insurance
Government
725 Participants
n=99 Participants
Insurance
Self-pay
42 Participants
n=99 Participants
Patient portal use in preceding year
700 Participants
n=99 Participants
Telehealth primary care visit in preceding year
398 Participants
n=99 Participants
COVID-19 hospitalizations per day in Utah, median
15.9 hospitalizations per participant
n=99 Participants

PRIMARY outcome

Timeframe: Through study completion, an average of 18 months for the intervention period and 12 months for the baseline period

The LCS care gap was considered closed if one or more of the following events occurred: (1) LDCT completion in the past year, (2) completion of another chest CT in the past year, or (3) SDM documentation in the past 3 years for eligible patients. To assess population care-gap closure levels at the end of each study period, we estimated the care-gap closure status for all patients who had primary care visits in the 12 months preceding the last day of the period. Using structured EHR data, SDM was considered documented if a clinician noted the need for LCS discussion was addressed, the patient declined screening, or LCS was not appropriate.

Outcome measures

Outcome measures
Measure
Patients Eligible for LDCT Lung Cancer Screening
n=1255 Participants
Patients aged 55-80 years who have smoked ≥30 pack-years and were a current smoker or quit smoking in the past 15 years.
Number of Participants With Lung Cancer Screening (LCS) Care-Gap Closed
588 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Through study completion, an average of 18 months for the intervention period

The number of participants who used the intervention was measured. The usage was measured through system logs and data from the enterprise data warehouse.

Outcome measures

Outcome measures
Measure
Patients Eligible for LDCT Lung Cancer Screening
n=1255 Participants
Patients aged 55-80 years who have smoked ≥30 pack-years and were a current smoker or quit smoking in the past 15 years.
Number of Participants Who Used the Intervention
168 Participants

Adverse Events

Patients Eligible for LDCT Lung Cancer Screening

Serious events: 0 serious events
Other events: 0 other events
Deaths: 26 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Kensaku Kawamoto, MD, PhD, MHS / Associate Chief Medical Information Officer

University of Utah

Phone: 801-581-4080

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place